February 03, 2025

FDA Monthly Round-Up: Key January Updates

January's FDA approvals include therapeutic advancements across neurology, oncology, pain management, and more.

Conexiant

January 30, 2025

Study Links Psoriasis to Elevated Sjögren’s Risk

The results highlight the need for clinicians to monitor psoriasis patients, especially those with PsA, for early signs of Sjögren’s syndrome.

Conexiant

January 21, 2025

Urinary Prostaglandins vs Calprotectin in IBD

Explore the latest study comparing urinary prostaglandin metabolites to fecal calprotectin for monitoring Crohn’s disease and ulcerative colitis activity.

Conexiant

January 17, 2025

Predictive Model for Difficult Psoriatic Arthritis Treatment

"According to the predictive model, the proposed D2T PsA definition identified a small subset of patients with increased treatment difficulty. These findings highlight the need for refining the criteria to better define D2T PsA patients."

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

January 07, 2025

Air Pollution’s Role in Autoimmune Risks, Genetic Causal Links

Research examines genetic links between air pollution and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.

Conexiant

April 30, 2024

Discovery of Novel Susceptibility Gene May Shed Light on Etiology of Psoriatic Arthritis Mutilans

Researchers may have uncovered genetic mechanisms underlying psoriatic arthritis mutilans.

Conexiant

June 12, 2024

FAc Implant Shows Sustained Improvement in Uveitis

Long-term study highlights effectiveness of fluocinolone acetonide implant in managing non-infectious posterior uveitis, maintaining stable intraocular pressure.

Conexiant

June 20, 2024

FDA Proposes Removal of Switching Study Requirement for Biosimilars

Explore the FDA's proposed changes for biosimilar drugs and their interchangeability, including expert insights on regulatory impacts and market dynamics.

Reuters